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ABSTRACT
Deficiencies in either growth hormone (GH) or insulin-like growth factor 1 (IGF-1) are associated with reductions in bone size during
growth in humans and animal models. Liver-specific IGF-1-deficient (LID) mice, which have 75% reductions in serum IGF-1, were created
previously to separate the effects of endocrine (serum) IGF-1 from autocrine/paracrine IGF-1. However, LID mice also have two- to
threefold increases in GH, and this may contribute to the observed pubertal skeletal phenotype. To clarify the role of GH in skeletal
development under conditions of significantly reduced serum IGF-1 levels (but normal tissue IGF-1 levels), we studied the skeletal
response of male LID and control mice to GH inhibition by pegvisomant from 4 to 8 weeks of age. Treatment of LID mice with
pegvisomant resulted in significant reductions in body weight, femur length (Le), and femur total area (Tt.Ar), as well as further
reductions in serum IGF-1 levels by 8 weeks of age, compared with the mean values of vehicle-treated LID mice. Reductions in both Tt.Ar
andLewereproportionalaftertreatmentwithpegvisomant. Ontheotherhand,therelativeamountofcorticaltissueformed(RCA)inLID
micetreated withpegvisomant wassignificantly less than that inboth vehicle-treated LIDand control mice, indicating that antagonizing
GHaction,eitherdirectly(throughGHreceptorsignalinginhibition)orindirectly(throughfurtherreductionsinserum/tissueIGF-1levels),
results in disproportionate reductions in the amount of cortical bone formed. This resulted in bones with significantly reduced
mechanical properties (femoral whole-bone stiffness and work to failure were markedly decreased), suggesting that compensatory
increases of GH in states of IGF-1 deficiency (LID mice) act to protect against a severe inhibition of bone modeling during growth,
which otherwise would result in bones that are too weak for normal and/or extreme loading conditions.  2011 American Society for
Bone and Mineral Research.
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Introduction
H
ormonal action through the growth hormone/insulin-like
growth factor 1 (GH/IGF-1) axis is an important regulator of
bone formation during growth. Secretion of GH stimulates IGF-1
productionintheliverandregulatesserumaswellastissueIGF-1
levels. Animal models have shown that gene ablation of IGF-1
results in reduced bone size and decreased bone mineral density
(BMD).
(1–3) In order to separate the effects of circulating
(endocrine) IGF-1 from tissue (autocrine/paracrine) IGF-1, we
previously created a liver-specific IGF-1 deficient (LID) mouse
model that has 75% reductions in serum IGF-1 levels. Skeletal
analysis of male LID mice throughout development revealed
impairment of transverse bone growth; beginning as early as
8 weeks and lasting into adulthood, bones were more slender
with significant reductions in the amount of cortical bone.
(4)
However, reductions in serum IGF-1 levels in LID mice were
accompanied by two- to threefold elevations in serum GH levels.
Thus the possibility exists that GH may regulate skeletal
development independent of hepatic IGF-1 (serum) via its
binding to the growth hormone receptor (GHR) in bone.
Numerous studies exist demonstrating the importance of GH
in mediating skeletal development. For example, growth
hormone receptor knockout (GHRKO) mice have decreased
femoral length, as well as decreased BMD, resulting from
reduced cortical bone area.
(5) Conversely, in human acromegaly,
excessive GH secretion has been linked to increased BMD
(6) and
is associated with a decrease risk of fracture.
(7) The proper
regulation of GH action has implications not only for growth but
also for aging and fracture risk. Specifically, GH-deficient patients
were found to have up to threefold increases in fracture
frequency compared with controls.
(8,9) In addition, there is
ORIGINAL ARTICLE J JBMR
Received in original form April 16, 2010; revised form August 26, 2010; accepted September 22, 2010. Published online October 6, 2010.
Addresscorrespondenceto:ShoshanaYakar,PhD,DivisionofEndocrinology,DiabetesandBoneDisease,Mount SinaiSchoolofMedicine,OneGustaveLLevyPlace,
Box 1055, New York, NY 10029-6574, USA. E-mail: shoshana.yakar@mssm.edu
Journal of Bone and Mineral Research, Vol. 26, No. 4, April 2011, pp 761–768
DOI: 10.1002/jbmr.265
 2011 American Society for Bone and Mineral Research
761evidence to support the idea that the age-specific onset of GH
deficiency may influence fracture risk.
(10) Although this literature
demonstrates the importance of GH in skeletal maintenance, GH
stimulates IGF-1 production, and the aforementioned studies did
not clarify what portion of GH’s effect is exerted through
secondary increases in serum IGF-1 levels and what effect, if any,
is exerted directly through GH action via the GHR.
To elucidatethe contribution ofcompensatory increases inGH
on bone development in the presence of reduced serum IGF-1
levels, we inhibited GH action in male LID mice by using the
growth hormone antagonist pegvisomant during pubertal
growth. Pegvisomant, by virtue of its G120K mutation, prevents
dimerization of the GHR and therefore all downstream
signaling.
(11,12) Pegvisomant has been well established as a
clinical approach to normalize serum IGF-1 levels in patients with
acromegaly,
(13)anditisalsoknowntonormalizemarkersofbone
formation and resorption.
(14,15) By administering pegvisomant to
LID mice, which have significantly reduced serum IGF-1 levels,
the contribution of GH to skeletal development can be assessed
independent of changes in hepatic IGF-1 production.
Methods
Animals
Male liver-specific IGF-1-deficient (LID) and control (Igf1
floxed)
mice (FVB/N background) were housed two to five per cage,
subjected to10-hour light/dark cycles, and given water and food
ad libitum. Mice were treated with either vehicle (saline) or a
growth hormone antagonist pegvisomant (Somavert, Pfizer, Inc.,
New York, NY, USA) three times a week for 4 weeks beginning at
4 weeks of age. Previously reported doses for pegvisomant
treatment have varied between approximately 0.5mg/mouse
per day
(16) and approximately 5mg/mouse per day.
(17) For
chronic treatment with pegvisomant, we chose a dose of 2mg/
mouse per day. Verification of this dose’s ability to inhibit GH
action in the liver was confirmed by a reduction in serum IGF-1
levels in control mice, as well as reductions in Igf1 and the acid-
labile subunit (Als) gene expression in liver 8hours following
pegvisomant injection. After 4 weeks of treatment (8 weeks old),
mice were euthanized for phenotypic analysis. The pubertal
period (4 to 8 weeks) was chosen for this investigation because
during this time serum GH levels peak and rapid changes in
femoral size and shape occur for both LID and control mice.
(4) All
animalswerelabeledwithcalcein(10mg/kg)7and2daysbefore
being euthanized. All procedures involving mice were reviewed
and approved by the Institutional Animal Care and Use
Committee of the Mount Sinai School of Medicine.
Serum parameters and gene expression
Serum IGF-1 levels were measured using a commercial radio-
immunoassay as described previously.
(18–20) Serum osteocalcin
wasmeasuredusingacommercial radioimmunoassay (American
Laboratory Products Company,Inc.,Salem,NH,USA).ForIgf1 and
Als gene expression, total RNA was extracted from liver samples
of control mice treated with vehicle or pegvisomant using TRIzol
in accordance with the manufacturer’s instructions (Invitrogen
Corp., Carlsbad, CA, USA).After verification of RNA integrity using
a Bioanalyzer (2100 Bioanalyzer-Bio Sizing, Version A.02.12 SI292,
Agilent Technologies, Santa Clara, CA, USA), 1mg of RNA was
reverse transcribed to cDNA using oligo(dT) primers with an
RT-PCR kit (Invitrogen Corp.). Real-time PCR analysis was
performed using the same primers.
Body composition
Body composition (fat and lean mass) was assessed in live
(nonanesthetized) animals using MRI (EchoMRI 3-in-1, Echo
Medical Systems, LLC, Houston, TX, USA). This technique
allowed serial measurements with high levels of precision.
The measurement of each mouse lasted 90seconds, and the
precision of the measurements was between 0.1 and 0.3 SDs.
Bone morphology and tissue mineral density
Femoral morphology of 8-week-old animals was assessed at an
8.7-mm voxel resolution using an eXplore Locus SP Pre-Clinical
Specimen Micro–Computed Tomography System (GE Health-
care, London, Ontario, Canada), as described previously.
(21)
Reconstructed images of mid-diaphyseal cortical bone (2-mm
region distal to the third trochanter) and distal metaphyseal
bone (2-mm region proximal to the growth plate) were
individually thresholded using a standard thresholding
algorithm that segmented bone from nonbone voxels. Recon-
structed whole-bone images also were obtained for measure-
ment of total femoral length (Le). Cortical parameters measured
included total area (Tt.Ar), cortical area (Ct.Ar), marrow area
(Ma.Ar), cortical thickness (Ct.Th), and polar moment of inertia
(Jo). In addition, we measured robustness, which was defined as
Tt.Ar/Le and indicates the extent of transverse bone size relative
to longitudinal bone size; smaller Tt.Ar/Le values indicate more
slender bones. We also measured relative amount of cortical
tissue formed (RCA), defined as Ct.Ar/Tt.Ar (a measure of how
much bone tissue exists in the total area of bone). The measured
trabecular parameters included bone volume fraction (BV/TV),
trabecular thickness (Tb.Th), trabecular number (Tb.N), and
trabecular spacing (Tb.Sp). Finally, for both cortical and
trabecular bone, tissue mineral density (TMD), which represents
the average mineral value of bone voxels expressed in
hydroxyapatite (HA) density equivalents, was calculated by
converting bone voxel grayscale values to mineral values (mg/cc
of HA) through the use of a calibration phantom containing air,
water, andhydroxyapatite (SB3,GamexRMI, Middleton,WI,USA).
Cortical bone histomorphometry
For dynamic histomorphometric measurements, right femurs of
8-week-old animals were cleaned and embedded in polymethyl
methacrylate (PMMA) as described previously.
(22) Embedded
sampleswere sectioned (200mmthickness)atthemid-diaphysis,
immediately distal to the third trochanter, using a low-speed
diamond-coated wafering saw (Buehler, Lake Bluff, IL, USA).
Sections were adhered to glass slides using Eukitt’s mounting
medium, and images of each section (5  magnification) were
obtained using a digital camera (Sony Exwave HAD, 3CCD
Camera, Sony, New York, NY, USA) attached to a fluorescence
microscope (Zeiss Axioplan2, Zeiss, Thornwood, NY, USA) with a
pixel resolution of 2.1mm. Bone formation was quantified
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surface (L.Pm/B.Pm, %), mineral apposition rate (MAR, mm/day),
and bone-formation rate (BFR/B.Pm, mm/day 100) were
measured using OsteoMeasure software (Osteometrics, Atlanta,
GA, USA), as defined previously.
(23)
Mechanical testing
After imaging by micro–computed tomography (mCT), left
femursfrom8-week-old malemicewereloadedtofailureinfour-
point bending at 0.05mm/s using a servohydraulic materials
testing system (Instron Corp, Canton, MA, USA) following
previously established protocols.
(24) Load and midspan deflec-
tion were acquired directly by an A/D system at a sampling
frequency of 25Hz. All mechanical testing was performed at
room temperature, and femur samples were kept moist with a
calcium-supplemented phosphate-buffered saline solution.
Load-deflection curves were analyzed for stiffness (the slope
of the initial portion of the curve), maximum load (the load at
breaking), postyield deflection (PYD), and work to failure (work).
PYD,ameasureofboneductility,wasdefinedasthedeflectionat
failure minus the deflection at yield. Yield was defined as a 10%
reduction of secant stiffness (load range normalized for
deflection range) relative to the initial (tangent) stiffness. Work
was defined as the area under the load-deflection curve.
Statistical analysis
Means and SDs for each trait were determined separately for the
treatment groups of each strain. Significant differences in mean
trait values of vehicle- and pegvisomant-treated animals of each
strain were identified using ANOVA and Bonferroni post-hoc
tests (p<.05) (Statistica 6.0, Statsoft, Inc., Tulsa, OK, USA). In the
case of serum IGF-1 levels, the data were log-transformed before
performing ANOVA to account for differences in sample
variance.
Fig. 1. GeneexpressionstudieswereperformedonmRNAextractedfromliversofcontrolandLIDmicetreatedwithvehicleorpegvisomant.(A)RT-PCRof
Als and Igf1 in control livers 8hours following pegvisomant injection indicated reductions when compared with vehicle-treated controls (b-actin served
as a loading control). (B) Real-time PCR analysis of Als and Igf1 24hours following pegvisomant injection showed significant reductions in control mice.
Igf1 gene expression was undetectable in LID mice, whereas Als gene expression was inhibited following pegvisomant injection.
Fig. 2. (A) Mean serum IGF-1 levels ( SD) for 8-week-old male control
and LID mice treated with vehicle (n¼15) or pegvisomant (n¼11).
(B) Mean serum osteocalcin levels ( SD) for 8-week-old male control
mice treated with vehicle (n¼10) or pegvisomant (n¼9) and LID mice
treated with vehicle (n¼9) or pegvisomant (n¼10).
 Significant differ-
ence between vehicle and pegvisomant treatment, ANOVA, p<.05.
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Pharmacologic inhibition of GH action reduces body size
and alters body composition
For this investigation, the pubertal period(4 to 8 weeks) was
chosenbecauseduringthistime,serumGHlevelspeakandrapid
changes in femoral size and shapeoccur for both LID and control
mice.
(4) To confirm that our selected dose of pegvisomant
successfully blocked GH action, we measured Als (a surrogate
marker for GH action) and Igf1 mRNA levels in control mice
treated with vehicle or pegvisomant. Eight hours after injection
(Fig. 1A) and 24hours after injection (Fig. 1B), control mice
treated with pegvisomant had significant reductions in Igf1 and
Als mRNA levels. LID mice, whether treated with vehicle or
treated with pegvisomant, showed undetectable levels of liver
Igf1 gene expression (as expected owing to gene recombina-
tion). In LID mice treated with vehicle, in which GH levels are
elevated, we could detect elevations in Als gene expression.
When treated with pegvisomant, Als gene expression in LID mice
was reduced significantly (Fig. 1B). These data are in accordance
with previously reported reductions in Igf1 mRNA levels after
acute treatment of mice with pegvisomant.
(17) As further
confirmation of pharmacologic inhibition, we found that
treatment of control mice with pegvisomant resulted in
significant reductions in serum IGF-1 levels by 8 weeks of age.
Interestingly, in LID mice, where the liver Igf1 gene is ablated,
serum IGF-1 levels after pegvisomant treatment (29 10ng/mL)
also were found to be statistically different from vehicle-treated
mice (57 9ng/mL; Fig. 2A), suggesting that GH-dependent IGF-
1 secretion from other tissues (muscle or fat) also was inhibited
by pegvisomant.
In both control and LID mice, significant reductions in body
weight and femoral length were observed after treatment with
pegvisomant (Fig. 3A, B). For mean body weight, the reduction in
pegvisomant-treated LID mice (approximately 15%) was sig-
nificantly greater than the reduction in control mice (approxi-
mately 8%). However, the reduction in mean femoral length (Le)
owing to pegvisomant was not significantly different between
LID (approximately 7%) and control mice (approximately 5%).
Quantification of body composition by MRI revealed that the
reduction in body weight was largely a result of a significant
decrease in absolute lean mass (ANOVA, p<.05) for both control
Fig. 3. Mean values for (A) body weight, (B) femur length, (C) relative lean mass, and (D) relative fat mass ( SD) for 8-week-old control and LID mice
treated with vehicle (n¼15 and n¼16, respectively) or pegvisomant (n¼10 and n¼11, respectively).
 Significant difference between vehicle and
pegvisomant treatment, ANOVA, p<.05.
764 Journal of Bone and Mineral Research COURTLAND ET AL.(16.86g before, 14.43g after) and LID (15.62g before, 12.47g
after) mice. Changes in absolute fat mass after pegvisomant
treatment were not significantly different for control (3.54g
before, 5.18g after) and LID (4.23g before, 4.20g after).
Consequently, for both control and LID mice, the percentage
of lean mass relative to body weight decreased significantly
(Fig. 3C), as expected owing to inhibition of GH, and the
percentage of fat mass relative to body weight increased
significantly (Fig. 3D) as a result of pegvisomant treatment.
Pharmacologic inhibition of GH action during puberty
leads to impaired bone accrual
In nearly all cases, the mid-diaphyseal cortical bone traits
affected by pegvisomant treatment were the same for control
and LID mice (Table 1). Ct.Ar, Ct.Th, RCA, and Jo all were
decreased significantly in control and LID mice, indicating
significant reductions in the amount of bone tissue (reduced
Ct.Ar, Ct.Th, and RCA), as well as a distribution of bone tissue
closer to the center of the marrow cavity (reducedJo). Tt.Ar
values also were reduced in both strains, but the reduction did
not reach statistical significance in the control mice. Ma.Ar,
robustness,andtissuemineraldensity(TMD)allwereunchanged
in both control and LID mice treated with pegvisomant. Finally,
for all cortical bone traits (Ct.Ar, Tt.Ar, Ma.Ar, Jo, Ct.Th, and TMD)
and derived traits (robustness and RCA), the mean values of
pegvisomant-treated control mice were statistically indistin-
guishable from those of vehicle-treated LID mice (ANOVA,
p<.05; Table 1).
Pegvisomant treatment resulted in only minor changes in the
trabecularbone ofcontrol mice,as evidenced by asmallincrease
in Tb.Th and trabecular TMD (Table 2). The relative amount of
bone tissue present (BV/TV) was unchanged, as was the number
and spacing of trabeculae. For LID mice, significant reductions
were seen in Tb.N, and as a result, Tb.Sp was increased
significantly. Tb.Th was unchanged in pegvisomant-treated LID
mice, and as in control mice, BV/TV and trabecular TMD were
unchanged.
Mechanical properties of femurs from treated mice were
assessed by four-point bending and correlated with bone
morphologic traits obtained by mCT. Control mice demonstrated
significant reductions in both stiffness and maximum load after
treatment with pegvisomant (Fig. 4A, B). In LID mice, the
reduction in stiffness did not reach significance, but maximum
load was reduced significantly. PYD and work also were reduced
significantly in LID mice but not in control mice (Fig. 4C, D).
Pharmacologic inhibition of GH action during puberty
hinders bone formation
Serum levels of the bone-formation marker osteocalcin were
reduced significantly in pegvisomant-treated control mice
compared with controls (Fig. 2B) but did not reach significance
in pegvisomant-treated LID mice. Mean values for L.Pm, MAR,
and BFR on the endosteal surface of the femoral midshaft were
statistically indistinguishable among all groups (no differences
were found when comparing strains or treatment groups)
(Table3). However, when comparing periosteal groups, although
L.Pm and MAR did not differ, mean BFR was significantly lower in
pegvisomant-treated control and LID mice than in their
respective vehicle-treated counterparts. This was due to lower
BFR values for animals that had double labels, as well as an
increase inthe number of animals that had no double labeling as
a result of pegvisomant treatment. Mean values for periosteal
BFR in pegvisomant-treated LID and control mice also were
significantly smaller than the mean BFR for all endosteal groups.
Similar surface differences were observed in L.Pm, which was
significantly smaller on the periosteal surface of pegvisomant-
treated animals than on the endosteal surface of these animals.
Table 1. Mean Cortical Bone Traits and Derived Traits ( SD) for
8-Week-Old Male Control and LID Mice Treated With Vehicle or
Pegvisomant
Control Vehicle n¼15 Pegvisomant n¼10
Tt.Ar (mm
2) 1.25 0.11 1.15 0.08
Ct.Ar (mm
2)
  0.64 0.05 0.56 0.04
Ma.Ar(mm
2) 0.61 0.07 0.59 0.04
Jo (mm
4)
  0.20 0.03 0.16 0.02
Ct.Th (mm)
  0.17 0.01 0.16 0.01
TMD (mg/cc) 1221 28 1232 33
Robustness (Tt.Ar/Le) 0.092 0.007 0.090 0.005
RCA (Ct.Ar/Tt.Ar)
  0.513 0.023 0.486 0.013
LID Vehicle n¼16 Pegvisomant n¼11
Tt.Ar (mm
2)
  1.12 0.12 1.00 0.12
Ct.Ar (mm
2)
  0.56 0.07 0.47 0.05
Ma.Ar(mm
2) 0.57 0.07 0.53 0.08
Jo (mm
4)
  0.16 0.04 0.12 0.03
Ct.Th (mm)
  0.16 0.01 0.14 0.01
TMD (mg/cc) 1221 37 1210 35
Robustness (Tt.Ar/Le) 0.084 0.008 0.081 0.010
RCA (Ct.Ar/Tt.Ar)
  0.497 0.020 0.467 0.022
 Significant difference between vehicle and pegvisomant treatment,
ANOVA, p<.05.
Table 2. Mean Trabecular Bone Traits ( SD) for 8-Week-Old
Male Control and LID Mice Treated with Vehicle or Pegvisomant
Control Vehicle n¼14 Pegvisomant n¼10
BV/TV (%) 14.7 2.7 15.1 1.6
Tb.Th (mm)
  0.028 0.002 0.032 0.001
Tb.N (mm
 1) 5.3 0.5 4.8 0.4
Tb.Sp(mm) 0.163 0.021 0.180 0.020
TMD (mg/cc)
  590 37 664 40
LID Vehicle n¼16 Pegvisomant n¼11
BV/TV (%) 16.7 5.0 12.6 5.3
Tb.Th (mm) 0.029 0.003 0.027 0.003
Tb.N (mm
 1)
  5.8 1.2 4.5 1.4
Tb.Sp (mm)
  0.153 0.045 0.215 0.072
TMD (mg/cc) 638 49 607 40
 Significant difference between vehicle and pegvisomant treatment,
ANOVA, p<.05.
GROWTH HORMONE ACTION ON THE PUBERTAL SKELETON Journal of Bone and Mineral Research 765Fig. 4. Mean values for (A) stiffness, (B) maximum load, (C) PYD, and (D) work ( SD) for 8-week-old control and LID mice treated with vehicle
(n¼15 each) or pegvisomant (n¼10 and n¼11, respectively).
 Significant difference between vehicle and pegvisomant treatment, ANOVA,
p<.05.
Table 3. Mean ( SD) Histomorphometry Data From Mid-diaphyseal Cortical Bone of 8-Week-Old Male Control (n¼9/Group) and LID
(n¼7/Group) Mice Treated With Vehicle or Pegvisomant
L. Pm (%)
MAR
(mm/day)
BFR/B. Pm
(mm/day
 100)
#Samples
Lacking Double Labels
Periosteal surface
Control (Vehicle) 30.8 8.9
b 2.8 1.3 91.1 46.3
d 1
Control (Pegvisomant) 22.1 11.4
b 1.6 1.1 45.9 32.2
c 2
LID (Vehicle) 29.6 14.1 2.5 1.2 85.7 44.9
e 1
LID (Pegvisomant) 25.6 12.4
b 1.6 1.6 57.3 55.3
c 3
Endosteal surface
Control (Vehicle) 60.1 12.2 2.3 0.7 136.2 47.2 0
Control (Pegvisomant) 71.6 12. 7 2.0 0.4 146.5 51.5 0
LID (Vehicle) 72.4 12.5 2.6 0.4 189.1 47.9 0
LID (Pegvisomant) 98.4 68.3
a 2.2 0.9 176.0 53.1 0
Statistical differences (ANVOVA, p<.05) are indicated by superscript letters.
aSignificantly different from all periosteal groups.
bSignificantly different from endosteal LID (Vehicle).
cSignificantly different for all other edosteal and perisosteal groups.
dSignificantly different from endosteal LID(Vehicle).
eSignificantly different from periosteal Control (Pegvisomant).
766 Journal of Bone and Mineral Research COURTLAND ET AL.Discussion
Our data indicate a role for GH in establishing pubertal skeletal
and body size that is independent of hepatic IGF-1 production.
We show that treatment with the growth hormone antagonist
pegvisomant resulted in significant decreases in body weight,
femur length, and skeletal acquisition in control mice but even
more prominent reductions in mice with reduced serum IGF-1
(LID mice). Specifically, inhibition of GH action resulted in
significant reductions in lean mass relative to body weight for
both groups, which was expected given that GH is known to
promote muscle and bone growth.
(25–28) In LID mice, where
serumIGF-1levelswereabout25%ofcontrollevels,thedecrease
in body weight owing to pegvisomant treatment was more
severe. These findings are in agreement with a prior study that
showed that Ghr/Igf1 nullizygotes have more severe growth
retardation than mice with single ablations of either the Ghr or
the Igf1 gene.
(29)
While inhibition of GH action in control mice during puberty
resulted in decreases in serum IGF-1 levels, as described
previously,
(17) in LID mice, in which the liver Igf1 gene was
ablated, treatment with pegvisomant decreased serum IGF-1
levelsanadditional 47%.Followingtreatment withpegvisomant,
control mice had significant reductions in cortical bone traits
(Ct.Ar, Jo, Ct.Th, and RCA; Table 1). Likewise, when LID mice were
treated with pegvisomant, further reductions in cortical bone
traits were observed, resulting in an even smaller cross-sectional
size (Tt.Ar and Jo), less total bone tissue (Ct.Ar), and less bone
tissue relative to bone area (RCA). In addition, femur length (Le)
was reduced significantly in pegvisomant-treated LID mice,
indicating reduced GH action in the femoral growth plate.
Interestingly, these reductions in femur length (Le) were
proportionally matched to reductions in transverse bone size
such that pegvisomant-treated LID mice (as well as control mice)
had identical robustness values when compared with vehicle-
treated animals. Thus loss of GH action during puberty appears
to hinder both transverse and longitudinal bone growth in a
coordinated fashion, whereas loss of hepatic IGF-1, as reported
previously in the LID mouse,
(4) reduces transverse bone growth
but not longitudinal growth, thereby resulting in a less robust,
more slender phenotype for LID mice (Fig. 5).
Reductions in cortical bone size and amount of bone tissue in
both control and LID mice treated with pegvisomant were
substantial, and this suggested that the bones would have
reduced mechanical properties. Testing under four-point
bending confirmed this hypothesis. Control mice treated with
pegvisomant had significantly reduced femur stiffness and
maximum load values. LID mice, which are at a mechanical
disadvantage to begin with, had even greater reductions in
maximum load, PYD, and work when treated with pegvisomant.
Given that reductions in PYD are often associated with variations
in bone tissue composition,
(30,31) we measured cortical TMD
values. However, no differences were found as a result of
antagonist treatment in LID mice. Still, other factors such as
mineral composition, mineral maturity, and collagen content
mayhavebeenalteredbythedualreductionsinserumIGF-1and
GH action, and this will require further investigation.
For both control and LID mice, inhibition of GH signaling
resulted in no changes to Ma.Ar, suggesting that reductions in
transverse bone size (Tt.Ar and Jo) were a result of inhibition of
periosteal bone apposition, not endosteal bone resorption. This
was further supported by our histomorphometric data, which
showed reduced L.Pm and BFR on the periosteal surfaces of
pegvisomant-treated control and LID mice compared with the
endosteal surfaces of these mice, which were unaffected by
pegvisomant treatment. It should be noted that inhibition of
periosteal surface bone dynamics has been reported previously
in untreated LID mice (reduced serum IGF-1 levels)
(4) and in Als
knockout (ALSKO) mice.
(32) Taken together, these data indicate a
surface-specific effect of the GH/IGF-1 axis during bone accrual.
In summary, our data suggest that in cases where hepatic
IGF-1 is diminished, elevations in GH may protect against a
severe inhibition of bone modeling during growth in an IGF-1-
dependent or -independent mechanism. Blockade of compen-
satory increases in GH in LID mice led to further decreases in
bone size and tissue amount, which resulted in the formation of
bones that may be too weak for normal or extreme loading
conditions. Thus GH appears important for matching tissue
amount (Ct.Ar) to bone size (Tt.Ar), bone length (Le) and body
size during puberty.
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Fig. 5. Schematic representation of mid-diaphyseal cortical bone from
8-week-old male mice after alterations in serum IGF-1 and GH levels. The
dottedlinesindicateareductioninTt.ArasaresultoflossofIGF-1andGH
action. Solid lines indicate no alteration in Ma.Ar as a result of diminished
IGF-1 or GH action. Reduction in serum IGF-1 (LID mouse) results in a
smaller, more slender bone compared with control mice by 8 weeks.
Reductionin GHactionat 4weeksresultsin furtherabrogationofskeletal
development in LID mice by 8 weeks such that the femurs are smaller.
However, size reductions in femur cross-sectional area are matched to
reductions in femur length such that GH blockade does not result in
bones that are more slender.
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